Sergio Fazio, MD

Sergio Fazio, MD

Director, Center for Preventive Cardiology

Professor of Medicine

Division of Cardiovascular Medicine

School of Medicine

Oregon Health Sciences University (OHSU)

Portland, OR

Related Videos

In your mind, as a Director of a Lipid Clinic and Preventive Cardiology Center, how do you apply the results of the ODYSSEY Outcomes and other trials in terms of the lack of safety signals when lowering LDL-C to levels < 50 mg/dL? Video

In your mind, as a Director of a Lipid Clinic and Preventive Cardiology Center, how do you apply the results of the ODYSSEY Outcomes and other trials in terms of the lack of safety signals when lowering LDL-C to levels < 50 mg/dL?

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment? Video

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?

What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab? Video

What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?

Given the reduction in both CV outcomes and associated, all-cause mortality, are the LDL-C thresholds currently recommended by the AHA and ESC low enough, and what are the implications for PCSK9-mediated CV risk reduction? Video

Given the reduction in both CV outcomes and associated, all-cause mortality, are the LDL-C thresholds currently recommended by the AHA and ESC low enough, and what are the implications for PCSK9-mediated CV risk reduction?

From a lipid medicine and preventive cardiovascular perspective, how do you triage the diabetic patient with ACS into a PCSK9-based treatment strategy for LDL-C reduction? Video

From a lipid medicine and preventive cardiovascular perspective, how do you triage the diabetic patient with ACS into a PCSK9-based treatment strategy for LDL-C reduction?

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy? Video

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?